Analyst consensus rating
Bristol-Myers Squibb Analyst Rating: Buy
Direct answer
Bristol-Myers Squibb's consensus rating is Buy.
24 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $66.21.
Forecast evidence checked September 4, 2026.
Get free Bristol-Myers Squibb email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $68.09
- Average price target
- $66.21
- High price target
- $80.00
- Low price target
- $40.00
- Low target gap
- -41.3%
- Target upside
- -2.8%
- High target gap
- +17.5%
- Target range width
- 58.7%
- Consensus rating
- Buy
- Analysts
- 24
- Evidence date
- September 4, 2026
- Valid through
- September 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Bristol-Myers Squibb?
Bristol-Myers Squibb has a verified Buy consensus. The same dataset has an average price target of $66.21.
How far are Bristol-Myers Squibb's low and high targets from the recorded price?
The low target implies -41.3%, while the high target implies +17.5%.
How many analysts are included in Bristol-Myers Squibb's consensus?
The verified consensus includes 24 analysts.
How is Bristol-Myers Squibb's target upside or downside calculated?
The average target of $66.21 is divided by the recorded price of $68.09, then one is subtracted to produce -2.8%. This does not guarantee a future return.
When was Bristol-Myers Squibb's analyst forecast verified?
The data was verified on 2026-09-04. The dataset is valid through 2026-09-11.